1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability

BACKGROUND: In the US, two common single-tablet regimens for HIV treatment are bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC). We sought to compare B/F/TAF and DTG/3TC in virologically suppressed, treatment-experienced people with HIV in the OPERA(®)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierone, Gerald, Fusco, Jennifer S, Brunet, Laurence, Sension, Michael, Dunbar, Megan, Gruber, Joshua, Dieterich, Douglas, Fusco, Gregory P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677299/
http://dx.doi.org/10.1093/ofid/ofad500.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677299/
http://dx.doi.org/10.1093/ofid/ofad500.054

Ejemplares similares